Company / SG&A Expense
Neurocrine Biosciences SG&A Expense History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest SG&A Expense
$1.2B
FY2025
5-year range
$583.3M / $1.2B
FY2021-FY2025
Trend
+14.8%
vs FY2024
Sector context
#22 of 211
Health Care
What the data says
Among 211 Health Care companies, Neurocrine Biosciences is in the bottom 10% for sg&a expense. SG&A Expense has increased for 9 consecutive years, from $68M in FY2016 to $1.2B in FY2025.
Based on SEC 10-K filings.
$1.2B in FY2025 with a 5-year CAGR of +21.7%. Top quartile in the Health Care sector.
Increased from $888M to $1.2B over the past 2 years.
Health Care sector context is included.
SG&A Expense over time
Growth rates
- 3-Year CAGR
- +15.4%
- 5-Year CAGR
- +21.7%
- 10-Year CAGR
- -
Sector benchmark
Bottom 10% in Health CareTop 90% of 211This company $1.2B Sector average $728.7M
▼
+58.7% above sector average
Key checks
Key Insights
- Neurocrine Biosciences's sg&a expense has grown for 9 consecutive years.
- 5-year CAGR of +21.7%, indicating consistent growth.
- In FY2025, sg&a expense increased 14.8% year-over-year.
- Ranks #22 out of 211 companies in the Health Care sector.
Company context
Key Data Points
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | SG&A ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $1.2B | +14.8% |
| FY2024 | $1.0B | +13.5% |
| FY2023 | $887.6M | +17.9% |
| FY2022 | $752.7M | +29.0% |
| FY2021 | $583.3M | +34.6% |
| FY2020 | $433.3M | +22.4% |
| FY2019 | $354.1M | +42.3% |
| FY2018 | $248.9M | +46.5% |
| FY2017 | $169.9M | +149.6% |
| FY2016 | $68.1M | +109.6% |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026